Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
104
resultados
Última actualización
21/06/2025 [08:47:00]
Resultados 50 a 75 de 104
Resumen de: AU2025203436A1
Abstract The present disclosure provides anti-CD19 antibodies and venetoclax for use in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or small lymphocytic lymphoma. The anti-CD19 antibodies, in particular MOR00208, and venetoclax are administered to patients suffering non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) according to a specific treatment paradigm to mitigate therapy associated tumor lysis syndrome.
Resumen de: WO2025117764A1
Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.
Resumen de: WO2025117672A1
The invention provides indazolyl-piperidine sulfonamide and related compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.
Resumen de: WO2025116570A1
The present invention relates to: a recombinant polypeptide specifically binding to B cells; and a composition for preventing or treating B cell lymphoma, comprising same as an active ingredient. The present invention can significantly improve direct killing activity against tumor cells by conjugating concanavalin A, which is a ligand of MPZL1, to an antibody molecule that recognizes a B cell-specific antigen such as CD20. Therefore, unlike therapeutic antibodies having main mechanisms of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and antibody-dependent cell-mediated phagocytosis (ADP), the recombinant polypeptide of the present invention does not depend on operating mechanisms of patient immune systems, and thus can be effectively used in an effective therapeutic composition even for cancer patients with reduced immune activity.
Resumen de: US2025177395A1
The compound of formula (1a) wherein p is 1 or 2, R1-R4 are hydrogen atom or the like, and a-d are 1 or 2, or a pharmaceutically acceptable salt thereof, which has an antitumor effect by inhibiting the binding between a MLL fusion protein that is infused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin
Resumen de: US2025177394A1
The invention provides inter alia methods of treating cancer comprising administering to a subject a cytidine triphosphate synthase 1 (CTPS1) inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor.
Resumen de: US2025179188A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: US2025177519A1
The present disclosure provides methods for treating multiple myeloma comprising administering an anti-CD38 antibody and an Interleukin-2 analog to an individual in need thereof and optionally administering Natural Killer (NK) cells having expression of CD38 reduced or knocked-out.
Resumen de: US2025177520A1
Methods of treating multiple myeloma by administering a bispecific antibody that binds to CD3 and BCMA to a patient in need are provided.
Resumen de: US2025177540A1
The present invention provides stable pharmaceutical compositions of pegylated carfilzomib compounds, methods for preparing the compositions, and uses of the compositions for treating cancer, including hematologic malignancies such as multiple myeloma. The compositions can be stored in frozen form or lyophilized to dry solid form.
Resumen de: WO2024054564A2
MicroOrganoSpheres (MOS) generated using cells from multiple myeloma bone marrow biopsies are provided herein, as are methods and materials for making and using such MOS.
Resumen de: WO2024026019A1
This disclosure relates to methods for treating cancer in a subject identified as having chronic myelomonocytic leukemia (CMML), comprising administering an anti-ILT3 antigen binding protein, or antigen binding fragment to the patient every three weeks (Q3W).
Resumen de: WO2024023313A1
The invention relates to genetically engineered mouse models for multiple myeloma (MM) and their uses thereof for the development of multiple myeloma models as well as for the screening of compounds suitable for the treatment of multiple myeloma.
Resumen de: CN118338900A
The present disclosure relates to compositions comprising nirogastat or a pharmaceutically acceptable salt thereof and methods of treatment.
Resumen de: NL2038217A
Disclosed is an application of chicken TRIM45 truncated recombinant protein or polyclonal antibody thereof. The invention discloses an application of chicken TRIM45 gene, recombinant vector, truncated recombinant protein or polyclonal antibody thereof in preparing anti-avian leukaemia virus related drugs, where the accession number of chicken TRIM45 gene Genbank is XM_0 70 7211. The truncated recombinant protein of chicken TRIM45 constructed by the invention avoids the defect of full-length expression stability, and meanwhile, the immune effect is more stable and the antibody level is higher. At the same time, the eukaryotic expression vector 10 and polyclonal antibody prepared by the invention can be applied to the research on the mechanism of chicken TRIM45' s regulation of ALV-J replication, which has far-reaching significance and makes up for the blank of chicken TRIM45 antibody preparation and research; It provides a new idea for the mechanism study of anti-ALV-J infection and immune regulation in chickens.
Resumen de: TW202430551A
A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.
Resumen de: AU2023367741A1
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies.
Resumen de: WO2025111214A1
The present invention relates to the use of roxadustat in the manufacture of a medicament for treating anemia in a subject having anemia associated with myelodysplastic syndrome (MDS). Methods for treating anemia in a subject having anemia associated with myelodysplastic syndrome comprising administering to the subject a therapeutically effective amount of roxadustat, thereby treating the anemia are also described.
Resumen de: WO2025108429A1
A chimeric antigen receptors (CARs) and CAR-NK cells targeting both BCMA and GPRC5D and use thereof in treating multiple myeloma (MM) is provided. In particular, the disclosure relates to bi-specific CARs comprising: (a) a B-cell maturation antigen (BCMA) targeting domain; and (b) a G protein-coupled receptor of family C, group 5, member D (GPRC5D) targeting domain, preferably armored with such as IL15, and the corresponding coding polynucleotides for the CARs and vectors comprising the polynucleotides. Also provided is CAR-NK cell modified with the CAR (s), and use of the CAR and CAR-NK cell in the treatment of MM.
Resumen de: WO2025111247A1
The present disclosure relates to methods of treating a subject having multiple myeloma, wherein the multiple myeloma has been determined to be refractory multiple myeloma, comprising administering to the subject a pharmaceutically acceptable form of Compound 1 and wherein the pharmaceutically acceptable from is selected from a gentisate form and a succinate form.
Resumen de: WO2025111533A1
This disclosure describes, in part, CAR-T cells comprising CDKN1B loss of function mutations, and method of using a BCMA binding CAR-T cell comprising a CDKN1B loss of function mutation to treat BMCA-expressing cancers (e.g., multiple myeloma).
Resumen de: US2025170125A1
This invention discloses use of (3-((1H-pyrazol3,4-bpyridine-5-substituted)ethinyl)-4-methyl-N-(4-((4-methylpiperazine-1-substituted)methyl)-3-(trifluoromethyl)phenyl)benzamide) and a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating acute lymphoblastic leukemia in particular precursor B-cell lymphoblastic leukemia.
Resumen de: US2025170174A1
Methods for treating leukemia are disclosed, comprising administering to a subject in need thereof therapeutically effective amounts of natural killer (NK)-derived exosomes. One non-limiting practical utilization of the NK-derived exosomes is induction therapy of acute myeloid leukemia (AML), to thereby immediately and effectively induce remission of the disease in newly diagnosed AML patients.
Resumen de: US2025170160A1
Methods of monitoring therapeutic efficacy in a subject with MDS are provided. Also provided is a method of identifying a subject with myelodysplastic syndrome (MDS) for treatment with a telomerase inhibitor, and methods of treating MDS. The subject methods can include administering to the subject an effective amount of a telomerase inhibitor and assessing the hTERT expression levels in a biological sample obtained from the subject. In some cases, a 50% or greater reduction in hTERT expression level identifies a subject who has an increased likelihood of benefiting from treatment with the telomerase inhibitor. The subject can be naive to treatment with a HMA, lenalidomide, or both. In some cases, the subject is classified as having low or intermediate-1 IPSS risk MDS and/or MDS relapsed/refractory to Erythropoiesis-Stimulating Agent (ESA). In some instances, the telomerase inhibitor is imetelstat sodium.
Nº publicación: US2025171535A1 29/05/2025
Solicitante:
JASPER THERAPEUTICS INC [US]
Jasper Therapeutics, Inc
Resumen de: US2025171535A1
Provided herein are compositions and methods related to depletion of diseased hematopoietic stem cells (HSC) using an anti-c-kit antibody. The compositions and methods described herein may be used to treat a subject in need of diseased HSC depletion due to a variety of diseases or disorders, such as myelodysplastic syndrome and acute myeloid leukemia.
BOPI
Sede Electrónica
